• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information


MethodsPhase II study, prospective.
Participants and Country47 patients with CUP: adenocarcinoma or PDC. 23/47 had favourable risk (predominantly nodal disease or peritoneal carcinomatosis).
InterventionsDocetaxel and carboplatin combination therapy
OutcomesOverall survival, time to progression, treatment response and toxicity
Prognostic factors (univariate)Age, performance status, serum tumour markers, number of sites, liver metastases, chemotherapy dose intensity and CUP risk group (only significant factors were reported).
Prognostic factors (multivariate)Not reported

From: Guideline chapter 3, Factors Influencing Management

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.